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Duc-Hau LeAbstract
Background: Protein complexes formed by non-covalent interaction among proteins play important roles in cellular
functions. Computational and purification methods have been used to identify many protein complexes and their cellular
functions. However, their roles in terms of causing disease have not been well discovered yet. There exist only a
few studies for the identification of disease-associated protein complexes. However, they mostly utilize complicated
heterogeneous networks which are constructed based on an out-of-date database of phenotype similarity network
collected from literature. In addition, they only apply for diseases for which tissue-specific data exist.
Methods: In this study, we propose a method to identify novel disease-protein complex associations. First, we introduce
a framework to construct functional similarity protein complex networks where two protein complexes are functionally
connected by either shared protein elements, shared annotating GO terms or based on protein interactions between
elements in each protein complex. Second, we propose a simple but effective neighborhood-based algorithm, which
yields a local similarity measure, to rank disease candidate protein complexes.
Results: Comparing the predictive performance of our proposed algorithm with that of two state-of-the-art network
propagation algorithms including one we used in our previous study, we found that it performed statistically significantly
better than that of these two algorithms for all the constructed functional similarity protein complex networks. In addition,
it ran about 32 times faster than these two algorithms. Moreover, our proposed method always achieved high
performance in terms of AUC values irrespective of the ways to construct the functional similarity protein complex
networks and the used algorithms. The performance of our method was also higher than that reported in some
existing methods which were based on complicated heterogeneous networks. Finally, we also tested our method
with prostate cancer and selected the top 100 highly ranked candidate protein complexes. Interestingly, 69 of them
were evidenced since at least one of their protein elements are known to be associated with prostate cancer.
Conclusions: Our proposed method, including the framework to construct functional similarity protein complex
networks and the neighborhood-based algorithm on these networks, could be used for identification of novel
disease-protein complex associations.
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Protein complexes are formed by non-covalent interac-
tions among proteins and have specific biological func-
tions. These protein complexes and their cellular
functions have been concurrently identified by a number
of methods based on protein interaction networks [1-3]
and affinity purification-mass spectrometry experiments
[4]. However, their particular roles in terms of causing
disease have not yet been well-determined. Indeed, all
protein complexes in a most updated database of protein
complexes CORUM [5] have been well functionally an-
notated and categorized; however, few of them have a
comment on their association with diseases.
It is shown that interactions among proteins forming
protein complexes do not only provide a better under-
standing of cellular functions, but also improve our under-
standing about human diseases [6-9]. A number of studies
have shown the association between protein complexes
and specific diseases. For instance, a protein complex of
SCRIB, NOS1AP and VANGL1 is associated with breast
cancer progression [10], TWIST/Mi2/NuRD protein
complex has an essential role in cancer metastasis [11],
aberrant protein complex consisting of prostaglandin-
d-synthase (PDS) and transthyretin (TTR) is a bio-
marker of Alzheimer’s disease [12]. In addition, past
studies show that mutations in multiple proteins that
form a protein complex may lead to the same disease
phenotype. Therefore, protein complexes can be used
to predict phenotypic effects of gene mutation and
identify human disease genes [8]. Some early studies
made use of protein complexes to predict novel disease
genes [13,14]. However, they did not use actual protein
complexes, but those simply assembled by neighboring
proteins [13] or generated from densely connected sub-
sets of ranked proteins [14]. In other words, the forma-
tion of such protein complexes was mainly based on
topological properties rather than functional similar-
ities of their protein elements. In addition, biological
relationships between protein complexes were also
omitted in those studies. Considering an observation
that if two protein complexes have biological relation-
ships (e.g., they share a number of common protein ele-
ments or their protein elements are highly physically
connected), the mutations of genes in one protein com-
plex can lead to same or similar phenotypes of the
other protein complex [15], the functional interaction
between protein complexes can play an important role
in predicting phenotypic effects of gene mutation. In-
deed, a recent study [16] used a heterogeneous network
consisting of a global protein complex network layer
and phenotype similarity network layer to predict novel
disease phenotype-gene associations. In that study, the
protein complex network layer was constructed using
existing human protein complexes and a human proteininteraction network. Then, a network propagation algo-
rithm was applied on the heterogeneous network to
prioritize candidate genes. Ultimately, they reported that
their method outperformed other methods which were
solely based on the human protein interaction network
and phenotype similarity network for the prediction of
novel disease phenotype-gene associations [17,18]. Taken
together, these studies indicate that the protein complexes
can be used to improve predictability of novel disease
phenotype-gene associations. However, identification of
novel direct disease-protein complex associations has not
yet been well-focused. Indeed, only a few studies have dir-
ectly focused on this problem recently [19-22]. For in-
stance, study [19] used a complicated heterogeneous
network including three layers (i.e., a phenotypic similarity
network layer, a tissue-specific protein interaction network
layer, and a protein complex membership layer), and then
applied a network propagation algorithm on that network
to discover disease-associated protein complexes. However,
the phenotype similarity network was collected from a rela-
tively old published study [23]; therefore it is not up-to-
date. In addition, they were also limited in the prediction of
disease of which a tissue-specific protein interaction net-
work [19] or gene expression data [22] exist. Having the
same limitation in using the out-of-date phenotype similar-
ity network as in [19], study [20] prioritized protein com-
plexes implicated in human diseases using a maximum
information flow algorithm on a heterogeneous network
which was constructed by combining a protein interaction
network and the phenotypic similarity network. Recently,
we also introduced a method for identification of disease
associated protein complexes using a random walk with
restart (Shortly called RWR) algorithm, which yields a glo-
bal similarity measure, on a constructed functional simi-
larity protein complex network. This method achieved
relative high performance [21]. However, the functional
similarity between protein complexes in the constructed
protein complex network was only based on their shared
protein elements.
In this study, we propose a novel method to identify
novel disease-protein complex associations. First, we
presented a framework to construct functional similarity
protein complex networks where each node is a protein
complex and two protein complexes are functionally
connected if they either share protein elements, share
annotating gene ontology (GO) [24] term or are con-
nected by protein interactions. Then, we proposed a novel
neighborhood-based algorithm (Shortly called NBH),
which yields a local similarity measure, to prioritize dis-
ease candidate protein complexes. We compared the per-
formance of our algorithm to two state-of-the-art network
propagation algorithms, RWR [21] and PRINCE [14], on
the three constructed functional similarity protein com-
plex networks. The performance of each algorithm was
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associations using a leave-one-out cross validation
method. The comparative results showed that NBH statis-
tically significantly outperformed that of the RWR and
PRINCE algorithms in predicting novel disease-protein
complex associations. In addition, NBH consumed less
running time in ranking candidate protein complexes than
that of the RWR and PRINCE algorithms. Moreover, rela-
tively high performances achieved for all the constructed
functional similarity protein interaction networks and the
three algorithms indicated the stability and feasibility of
our proposed method for the identification of novel dis-
ease associated protein complexes. Furthermore, a case
study on prostate cancer was performed. As a result, 69
out of top 100 highly ranked protein complexes were
shown to be associated with prostate cancer.
Methods
Databases of protein complexes and disease
phenotype-gene associations
First, we obtained 1,704 human protein complexes from a
database of mammalian organisms protein complex
CORUM [5] (See in Additional file 1: Table S1). These
protein complexes were manually annotated with their
functions, localization, subunit composition and literature
references. Then, we used known disease phenotype-gene
associations from OMIM [25] to construct known disease
phenotype-protein complex associations.
Construction of known disease phenotype-protein complex
associations
To our knowledge, there is no standard database of
disease-protein complex associations in public resources.
Therefore, based on an observation from a number of
studies that mutations in multiple proteins that form a
protein complex may lead to the same disease [7,8,26-29],
we defined a known disease phenotype-protein complex
association as follows: a protein complex is associated with
a disease phenotype if at least one of its protein elements
is associated with the disease phenotype. Based on this
definition of the association, the set of collected human
protein complexes and the set of known disease
phenotype-gene associations, we constructed 282 disease
phenotypes and their known associated protein complexes
(See in Additional file 1: Table S2).
Construction of functional similarity protein complex
networks
A protein complex is formed by structurally and func-
tionally related protein elements. Indeed, protein ele-
ments within a protein complex have higher GO-based
semantic similarities than that on all proteins [30]. In
addition, protein complexes often correspond to func-
tionally and structurally cohesive substructures/denselyconnected regions in protein interaction network [31,32].
Therefore, to construct functional similarity protein com-
plex networks where each node is a protein complex, we
defined a functional similarity interaction between two
protein complexes based on: i) shared protein elements; ii)
shared annotating GO terms; and iii) protein interactions.
Figure 1 shows an illustrative example of the construction
of functional similarity interactions between two protein
complexes.
Given two protein complexes Ci = {pk|k = 1…m} and
Cj = {pl|l = 1…n}, where pk, pl are protein elements of Ci
and Cj, m and n are the number of protein elements be-
longing to Ci and Cj, respectively, we here defined three
kinds of functional similarity interactions between Ci
and Cj based on shared protein elements, shared anno-
tating GO terms and protein interactions.
A functional similarity interaction between two protein
complexes based on their shared protein elements
A protein complex is formed by functionally related pro-
tein elements. Therefore, it could be accepted that the
more number of protein elements two protein complexes
share, the more functionally related they are. Indeed, it
was shown that this kind of interaction not only reflects
physical interaction of complexes, but may also represent
common regulation, localization, turnover or architecture
[33]. Therefore, as we did in our previous study [21], we
defined a functional similarity interaction between two
protein complexes based on their shared protein elements
as follows: Two protein complexes are functionally inter-
acted with each other if they share at least one protein
element. And, a weight of this interaction is number of the
shared protein elements normalized by number of ele-
ments of a protein complex which has a smaller number
of elements. It is formally defined as follows:
SC¼ Ci∩Cjj jmin Cij j; Cjj jð Þ
Based on this definition and the set of collected human
protein complexes, we constructed a functional similarity
protein complex network including 1,579 nodes and
16,981 interactions (shortly called SharedProteinComNet).
A functional similarity interaction between two protein
complexes based on their shared annotating GO terms
Functions of each protein elements are described by anno-
tating GO terms. Therefore, we additionally constructed a
functional similarity interaction between two protein com-
plexes based on shared annotating GO terms, where a list
of genes and annotating GO terms were collected from
NCBI Entrez Gene FTP site (ftp://ftp.ncbi.nlm.nih.gov/
gene/DATA/gene2go.gz). More specifically, we defined the
interaction based on a measure of gene functional similarity
Figure 1 An illustrative example of construction of functional interactions between two protein complexes. Protein complexes 13S condensing
(ID: 10) and DNA ligase IV-condensin (ID: 353) compose of five and three protein elements, respectively. Functional interactions between these two
protein complexes are specified based on shared protein elements, shared annotating GO terms, or protein interactions.
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functionally interacted with each other if they share at least
one annotating GO term, where annotating GO terms in-
clude direct annotating GO terms and their ancestors in
the GO directed acyclic graph. Then, weight of the inter-
action is defined as number of the shared annotating GO
terms normalized by number of annotating GO terms of a
protein complex whose protein elements were annotated
with smaller number of annotating GO terms. Formally, a
functional similarity interaction between Ci and Cj is de-





min GOCij j; GOCj
  
where GOCi, GOCj are sets of GO terms annotating to
protein elements in Ci and Cj, respectively.
As in [34], GOCi and GOCj are defined as follows:
GOCi ¼ ∪m
k




GOl∪anc GOlð Þð Þ
where: GOk and GOl are set of direct annotating GO terms
of protein pk and pl, respectively; anc(GOk) and anc(GOl)are ancestors of GOk and GOl excluding root terms (i.e.,
GO:0008150 for biological process, GO:0005575 for cellu-
lar component and GO:0003674 for molecular function)
in GO directed acyclic graph of each sub-category,
respectively.
For each GO sub-category, we constructed a func-
tional similarity protein complex network. Then we inte-





where M is number of networks containing interaction
between protein complex Ci and Cj. (SC)k is functional
similarity interaction between Ci and Cj in network k.
Consequently, we constructed a functional similarity
protein complex network including 1,683 nodes and
1,415,266 interactions based on annotating GO terms
(shortly called SharedGOTermComNet).
A functional similarity interaction between two protein
complexes based on their shared protein interactions
A past study proposed a method to measure a functional
relationship between two gene sets based on protein
interaction network [35]. By considering a protein com-
plex a special case of a gene set, the study showed that
protein complexes with high functional similarities tend
to be involved in the same functional catalogue and
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prioritizing candidate cancer-associated protein com-
plexes [35]. In this study, we additionally used that
method to define a functional similarity interaction be-
tween two protein complexes based on protein inter-
action network. To this end, we collected a human
physical protein interaction network (PPI) consisting of
10,486 genes and 50,791 interactions from the NCBI
Entrez Gene FTP site (ftp://ftp.ncbi.nlm.nih.gov/gene/
GeneRIF/interactions.gz). This network was constructed
by integrating BIND [36], BioGRID [37] and HPRD [38].
Formally, a functional similarity interaction between Ci
and Cj was defined based on protein interactions among








SP pk ; plð Þ
m n
Where
SP pk ; plð Þ ¼ 1 if pk≡pl or pk ; pl∈Ci∩CjLength of shortest path between pk and pl

Based on this definition, the set of collected human
protein complexes and the human physical protein inter-
action network, we constructed a functional similarity
protein complex network including 1,681 nodes and
1,412,040 interactions based on protein interactions
(shortly called SharedPPIComNet).
Network-based ranking algorithms
Given a connected weighted graph G(V, E) with a set of
nodes V = {v1, v2, …, vN} and a set of links E = {(vi, vj)| vi,
vj∈V}, a set of source nodes S ⊆ V and a N ×N adjacency
matrix W of link weights. Here, we are going to introduce
our proposed neighborhood-based algorithm. In addition,
we also briefly describe the RWR algorithm, which was
used in our previous study [21], and the PRINCE algo
rithm [14]. These three algorithms will be used for meas-
uring relative similarity of node vi to S. By modelling a
functional similarity protein complex network as a graph
(i.e., nodes present protein complexes, links present func-
tional interactions among protein complexes, W presents
pair-wise similarities between protein complexes, and S
presents known disease-associated protein complexes), a
ranking of candidate protein complexes based on their
relative similarity to S is to predict novel disease-associated
protein complexes. The relative similarity also measures
how relevant to a disease a candidate protein complex is.
The proposed neighborhood-based algorithm
The neighborhood-based algorithm (shortly called NBH)
was based on direct neighbors of source nodes (S).Formally, the relative similarity of a node vi to a set of





where wij is weight of link (vi, vj). This score is 0 for
nodes not connected to any source nodes.
Random Walk with Restart (RWR)
RWR is a variant of the random walk [39] and it mimics
a walker that moves from a current node to a randomly
selected adjacent node or goes back to source nodes
with a back-probability γ ∈(0, 1). RWR can be formally
described as follows:
Ptþ1 ¼ 1−γð ÞW 0Pt þ γP0
where Pt is a N × 1 probability vector of |V| nodes at a
time step t of which the ith element represents the prob-
ability of the walker being at node vi∈V, and P
0 is the
N × 1 initial probability vector where the value of an
element corresponding to a non-source node or a source
node is zero or 1/|S|, respectively. The matrix W’ is rep-
resented by a transition probability matrix and thus
(W’)ij, the (i, j) element in W’, denotes a probability with
which a walker at vi moves to vj among V\{vi}. Formally,
it is defined as follows:




where (Vout)i is a set of outgoing nodes of vi.
All nodes in the network are eventually ranked accord-
ing to the steady-state probability vector P∞, which is ob-
tained by repeating the iterations until ||Pt+1-Pt|| < 10−6 in
this study.
PRINCE
Study [14] introduced PRINCE for disease gene predic-
tion. Similar to RWR, PRINCE is a kind of network
propagation algorithm, it simulates a process where
nodes for which prior information exists pump informa-
tion to their neighbors though an iteration process. At
each iteration, every node propagates the information re-
ceived at the previous iteration to its neighbors. PRINCE
can be formally described as follows:
Ptþ1 ¼ αW 0Pt þ 1−αð ÞP0
where P0 represents a prior knowledge function. Similar
to RWR, in this study, it is the N × 1 initial probability
vector where the value of an element corresponding to a
non-source node or a source node is zero or 1/|S|, re-
spectively. The first part of the equation represents the
smooth propagation process which assigns similar values
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knowledge. Trade-off parameter α ∈(0, 1) weighs the
relative importance of these constraints with respect to
one another. Different from RWR, The matrix W’ is rep-
resented by a row-normalized matrix and defined for-
mally as follow:
W 0ð Þij ¼
Wð ÞijﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃX
k∈ V inð Þi
Wð Þki 
X
l∈ V inð Þj
Wð Þlj
r
where (Vin)i and (Vin)j are a set of incoming nodes of vi
and vj, respectively.
Similarly to the RWR algorithm, all nodes in the net-
work are eventually ranked according to the steady-state
probability vector P∞, which is obtained by repeating the
iterations until ||Pt+1-Pt|| < 10−6 in this study.
Performance evaluation
Ranking performance was assessed through the leave-one-
out cross-validation (Shortly called LOOCV) process. Let
us assume that a functional similarity protein complex
network G(V, E), a set of known disease-associated protein
complexes (D ⊆ V) and a set of candidate protein com-
plexes (C) are given. A protein complex s∈D was held out
for validation and the remaining known disease-associated
protein complexes were specified to a set of source nodes
(i.e., S =D\{s}). The network-based ranking algorithms
were used to prioritize all the candidate protein com
plexes. This process was repeated by setting every s∈D to
a held-out protein complex. For a reliable performance
comparison, we drew the receiver operating characteristic
(ROC) curves and computed the area under the curve
(AUC) based on the rank of held-out protein complex s
and candidate protein complexes in set C∪{s}. More spe-
cifically, given a threshold τ, we counted TP (true positives),
FN (false negatives), FP (false positives), and TN (true




I rank sð Þ≤τð Þ FN¼
X
s∈D




I rank cð Þ≤τð Þ TN¼
X
c∈C
I rank cð Þ>τð Þ
where rank(s), rank(c) and I(∙) denote the rank of s, the
rank of a candidate protein complex c out of the set
C∪{s} and the indicator function, respectively. Then, we





By varying τ from one to the number of protein com-
plexes in the set C∪{s}, the relationship between sensitiv-
ity and (1-specificity) was plotted. The ROC curve is thecurve constructed based on those pairs of values, and
the AUC is the area under the ROC curve. In this study,
we considered candidate protein complexes set as all
protein complexes that are not known to be associated
with the disease (i.e.,V\D) in G.
Results and discussion
Performance comparison
Due to using LOOCV method, we collected only 270 dis-
ease phenotypes which are known to be associated with at
least two protein complexes to assess the performance of
each algorithm. For RWR and PRINCE algorithm, we var-
ied back-probability and trade-off parameters respectively
in a range of [0.1, 0.9]. The AUC values were calculated
for each disease phenotype on each individual functional
similarity protein complex network. Then, the perform-
ance of each algorithm was averaged over those disease
phenotypes for each individual functional similarity pro-
tein complex network. Figure 2 shows that the perform-
ance of NBH was statistically significantly better than that
of RWR and PRINCE (i.e., All P-values < 0.05 using two
sample t-Test. See more detail in Table 1).
Another advance of NBH compared to RWR and
PRINCE is that NBH is free of parameters, whereas the
performance of RWR and PRINCE is controlled by
back-probability and trade-off parameters, respectively.
Indeed, Figure 2 shows that the performance of RWR
was improved when back-probability increases (i.e.,
slopes of regression lines for RWR in Figure 2(a), (b)
and (c) are 0.00230, 0.22108 and 0.20141 with P-values
are 0.00307, 0.00409, 0.005 using ANOVA test for re-
gression, respectively). In contrast, the performance of
PRINCE declined when trade-off increases (i.e., slopes of
regression lines for PRINCE in Figure 2(a), (b) and (c)
are −0.00147, −0.03838 and −0.08100 with P-values are
0.00015, 0.02758, 0.00714 using ANOVA test for regres-
sion, respectively). This opposite trends of RWR and
PRINCE is because RWR and PRINCE algorithms are
generally similar in that the first part of RWR and
PRINCE represents the smooth propagation process
which assigns similar values to adjacent nodes, while the
second part represents prior knowledge. However, the
parameters affect inversely for each algorithm (i.e., when
back-probability increases the random walker of RWR
tend to go back to the source nodes and therefore give
higher score for nodes nearby source nodes. In contrast,
when trade-off increases the random walker of PRINCE
tends to go far from source nodes and therefore assign
lower score for nodes nearby source nodes). Figure 2
also shows that RWR and PRINCE achieved best per-
formance when back-probability and trade-off parame-
ters are set to 0.9 and 0.1, respectively. This observation
implied that by linking protein complexes by functional
interactions, protein complexes associated with the same
Figure 2 Performance comparison between network-based ranking algorithms on different functional similarity protein complex networks.
(a) SharedProteinComNet. (b) SharedGOTermComNet. (c) SharedPPIComNet. For RWR and PRINCE, back-probability and trade-off parameters were
varied in a range of [0.1, 0.9], respectively. Vertical axis represents average AUC values over 270 disease phenotypes.
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closely. This is also the reason why NBH, which is only
based on neighbors of known disease protein complexes,
achieved better performance than that of RWR and
PRINCE.
In addition, we observed that the performance of RWR
shows less positive trend in SharedProteinComNet than
that in SharedGOTermComNet and SharedPPIComNet
(i.e., the slopes of regression lines are 0.00230, 0.22108
and 0.20141, respectively), and PRINCE was shown less as
a negative trend in SharedProteinComNet than that in
SharedGOTermComNet and SharedPPIComNet (i.e., theTable 1 Performance comparison between network-based ran
complex networks
# Protein complex network NBH
1 SharedProteinComNet 0.99665 (±0.00988)
2 SharedGOTermComNet 0.95869 (±0.07599)
3 SharedPPIComNet 0.97704 (±0.05926)
–P-values represent the statistical significance of performance comparison between
t-Test for mean assuming unequal variances.
–Data in each cell represent mean (±standard deviation).
–Performance of NBH is statistically significantly better than that of RWR and PRINC
and #3 are detail performance comparison of the three algorithms on SharedProtein
to Figure 2(a), (b) and (c), respectively.slopes of regression lines are −0.00147, −0.03838 and
−0.08100, respectively). Considering the network density
of SharedProteinComNet was much lower than that in
SharedGOTermComNet and SharedPPIComNet (i.e., the
network densities are 0.014, 0.999 and 1, respectively), this
observation indicated that disease protein complexes are
more connected in SharedGOTermComNet and Share-
dPPIComNet. However, networks with very high densities
such as SharedGOTermComNet and SharedPPIComNet,
may contain unreliable functional interactions that
can reduce the performance of the methods. Indeed,
Figure 3 shows that the performance of all algorithmsking algorithms on different functional similarity protein
RWR PRINCE
0.99134 (±0.01663) 0.99174 (±0.01633)
(P-value = 4.37 × 10−14) (P-value = 1.7 × 10−12)
0.90671 (±0.10804) 0.94305 (±0.08432)
(P-value = 1.28 × 10−27) (P-value = 8.2 × 10−4)
0.92646 (±0.12794) 0.96257 (±0.08166)
(P-value = 1.28 × 10−27) (P-value = 1.51 × 10−4)
NBH and RWR/PRINCE algorithms. They were calculated using two-sample
E for all three functional similarity protein complex networks. Data row #1, #2
ComNet, SharedGOTermComNet and SharedPPIComNet networks corresponding
Figure 3 Performance comparison between functional similarity protein complex networks on different network-based ranking algorithms.
(a) NBH. (b) RWR. (c) PRINCE. For RWR and PRINCE, back-probability and trade-off parameters were varied in a range of [0.1, 0.9], respectively.
Vertical axis represents average AUC values over 270 disease phenotypes.
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SharedGOTermComNet and SharedPPIComNet (i.e.,
All P-values < 0.05. See more detail in Table 2).
To test the hypothesis of whether density affect the
performance of the algorithms, we varied a threshold (t)
of interaction weight to extract different functional simi-
larity protein complex networks of which interactions
having weight no less than t. Particularly, for SharedGO-
TermComNet and SharedPPIComNet, we additionally
extracted five networks corresponding to t = 0.1, 0.3, 0.5,
0.7, and 0.9. Figure 4 shows the performance of each al-
gorithm on SharedGOTermComNet and SharedPPICom-
Net with different thresholds. As observed, for NBH
(Figure 4(a) and (b)), the best performance was achieved
with “All” (i.e., SharedGOTermComNet and SharedPPI-
ComNet) and decreased when the threshold increased.
However, for RWR (Figure 4(c) and (d)) and PRINCE
(Figure 4(e) and (f )), it performed best and most stable
with t = 0.7 or t = 0.9. This result indicated these two al-
gorithms perform better when unreliable functional in-
teractions were eliminated.
In addition to comparison of prediction performance
of the proposed algorithm with RWR and PRINCE, we
here show its advance in running time. To this end, we
ran each method for 282 disease phenotypes, where their
known disease associated protein complexes were used
as source nodes. For RWR and PRINCE, we also varied
back-probability and trade-off parameters in a range of[0.1, 0.9] and took the average of running time over this
range. The final running time for each disease phenotype
was averaged over the set of 282 disease phenotypes.
Table 3 shows the comparison on the running time of
different algorithms. It was obvious that our proposed
algorithm run faster than both RWR and PRINCE about
32 times averaging on all the three functional similarity
protein complex networks.
To our knowledge, only a few studies have directly
been proposed for identification of disease-associated
protein complexes [19-22]. In which, as showed in the
previous section, NBH algorithm outperformed RWR,
which was used in our previous study [21], in both pre-
diction performance and running time for all the three
constructed functional similarity protein complex net-
works. Meanwhile, the study [22] was specifically pro-
posed to identify cancer-associated protein complexes
based on gene expression data and it did not show the
over prediction performance. For the two remaining
studies, they used network propagation [19] and a max-
imum information flow [20] algorithms on complicated
heterogeneous networks. For instance, study [19] con-
structed a heterogeneous network including three layers
including a disease phenotype similarity network layer, a
tissue-specific protein interaction network layer and a
protein complex membership layer, then they applied
the RWR algorithm on this heterogeneous network. Be-
sides using an out-of-date disease phenotype similarity
Table 2 Performance comparison between functional similarity protein complex networks on different network-based
ranking algorithms
# Algorithm SharedProteinComNet SharedGOTermComNet SharedPPIComNet
1 NBH 0.99665 (±0.00988) 0.95869 (±0.07599) 0.97704 (±0.05926)
(P-value = 6.74 × 10−15) (P-value = 8.43 × 10−8)
2 RWR 0.99134 (±0.01663) 0.90671 (±0.10804) 0.92646 (±0.12794)
(P-value = 1.06 × 10−252) (P-value = 7.61 × 10−122)
3 PRINCE 0.99174 (±0.01633) 0.94305 (±0.08432) 0.96257 (±0.08166)
(P-value = 7.14 × 10−151) (P-value = 1.14 × 10−63)
–P-values represent the statistical significance of performance comparison between SharedProteinComNet and SharedGOTermComNet/SharedPPIComNet networks.
They were calculated using two-sample t-Test for mean assuming unequal variances.
–Data in each cell represent mean (±standard deviation).
–Performance of SharedProteinComNet is statistically significantly better than that of SharedGOTermComNet and SharedPPIComNet for all three network-based
ranking algorithms. Data row #1, #2 and #3 are detail performance comparison of the three functional similarity protein complex networks by NBH, RWR and
PRINCE algorithms corresponding to Figure 3(a), (b) and (c), respectively.
Figure 4 Investigation of the performance of each method on different functional similarity protein complex networks extracted with different
thresholds (t). (a), (c) and (e) are the performance of NBH, RWR and PRINCE for networks which are extracted from SharedGOTermComNet,
respectively; (b), (d) and (f) are the performance of NBH, RWR and PRINCE for networks which are extracted from SharedPPIComNet, respectively.
For RWR and PRINCE, back-probability and trade-off parameters were varied in a range of [0.1, 0.9], respectively. Vertical axis represents average
AUC values over 270 disease phenotypes. “All” is the original functional similarity protein complex networks (i.e., SharedGOTermComNet in
(a), (c) and (e); SharedPPIComNet in (b), (d) and (f)).
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Table 3 Running time (millisecond) comparison between network-based ranking algorithms on different functional
similarity protein complex networks
NBH (A) RWR (B) PRINCE (C) Speedup (B/A) Speedup (C/A)
SharedProteinComNet 2 79 81 41.8 42.6
SharedGOTermComNet 110 3369 3428 30.6 31.2
SharedPPIComNet 115 2544 2497 22.2 21.8
Average 31.5 31.9
–Platform: Intel Core i3 3240 CPU 3.4GHz, 4GB RAM.
–Average running time for ranking all candidate protein complexes on functional similarity protein complex networks of a disease phenotype.
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apply to only disease phenotypes of which a tissue-
specific protein interaction network exist. Similarly, in
the study [20], they also constructed a heterogeneous
network including a disease phenotype similarity net-
work layer and protein interaction network layer, in
which the disease phenotype similarity network was also
collected from literature [23]. It is obvious that, these
two methods based on networks that are different from
ours. Therefore, it is unfeasible to compare directly the
performance of our proposed method with them. How-
ever, the best reported performances of these methods
are inferior to ours (i.e., the performance in term of
AUC value is about 0.88 and 0.92 in the study [19] and
study [20], respectively; whereas the worst case for NBH
is about 0.96 (See Table 1)).
Case study: prostate cancer
Prostate cancer (MIM ID: 176807) is a complex disease and
there were 22 genes associated with it as published in
OMIM [25]. Following the definition of a known disease
phenotype-protein complex association (See Methods
section), we found that 12 protein complexes were
known to be associated with prostate cancer (See in
Additional file 1: Table S2). These associated protein
complexes were set as source nodes and all others as
candidates in SharedProteinComNet. After applying
NBH to rank all candidates, we selected 100 highly
ranked candidate protein complexes. By searching asso-
ciations between 219 genes coding proteins involved in
those selected protein complexes with prostate cancer
on GeneRIF [40] (ftp://ftp.ncbi.nih.gov/gene/GeneRIF/
generifs_basic.gz), we found 28 of them reported to be
associated with prostate cancer (See in Additional file 1:
Table S3). These protein-coding genes are involved in 69
protein complexes in the top 100 selected protein com-
plexes. For instance, overexpression of Skp2 in protein
complex “Ubiquitin E3 ligase (SKP1A, SKP2, CUL1,
RBX1)” (ID: 1051) is associated with recurrence following
radical prostatectomy in prostate cancer [41]. In addition,
lower levels of nuclear beta-catenin in protein complex
“JUN-TCF4-CTNNB1 complex” (ID: 1816) is associated
with prostate cancer progression [42]. Elevated BRCA1
and NBN truncating mutation in protein complex“BRCA1-RAD50-MRE11-NBS1 complex” (ID: 202) are as-
sociated with prostate cancer [43,44] . Beside the 69 evi-
denced protein complexes, others in the top 100 ranked
protein complexes can be candidates for future validation
(See in Additional file 1: Table S4).
To make the results for identification of novel prostate
cancer-associated protein complexes more convincing,
we additionally randomly selected 200 sets of 100 pro-
tein complexes among protein complexes in the same
functional similarity protein complex network. Then, we
repeated the same procedure as we did for the 100
highly ranked candidate protein complexes to find novel
prostate cancer-associated protein complexes for each set.
The result showed that, on average, about 28 protein com-
plexes in each set were enriched with genes which are as-
sociated with Prostate cancer (See in Additional file 1:
Table S5). Therefore, the set of 100 highly ranked candi-
date protein complexes has more prostate cancer associa-
tions than expected by chance (P-values = 2.9 × 10−200,
using one-sample t-Test).
Conclusions
Protein complexes play important roles in cellular func-
tions; however, their roles in causing disease have not
been paid enough attention because there have been a
few studies directly focusing on identifying disease-
protein complex associations. In this study, we have pro-
posed a novel method for identification of novel disease
associated protein complexes. Comparing to our previous
study [21], which used RWR algorithm on a functional
similarity protein complex network built based on shared
protein elements, in this study, we presented a framework
to construct functional similarity protein complex net-
works based on not only shared protein elements, but also
shared annotating GO terms and protein interactions. In
addition, we proposed a novel neighborhood-based algo-
rithm to prioritize candidate disease protein complexes.
Comparing the performance of our proposed algorithm
with that of the two state-of-the-art algorithms (i.e., RWR
and PRINCE, which yields global similarity measure), we
found that our proposed algorithm outperformed these
two algorithms for all the three constructed functional
similarity protein complex networks. In addition, it also
consumed less running time than these algorithms in
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phenotype. Moreover, our proposed algorithm is free of
parameters; meanwhile the performance of RWR and
PRINCE is controlled by back-probability and trade-off
parameters, respectively. Comparing the performance of
our proposed method with that of other methods also pro-
posed for identification of disease associated protein com-
plexes, we found that our proposed method is simpler
since it is only based on homogeneous network of protein
complexes (i.e., the three functional similarity protein
complex networks only contain protein complexes as
nodes), meanwhile other methods were based on a com-
plicated heterogeneous networks in which a node can be
either protein, protein complex or disease phenotype. In
addition, the best reported performances of these methods
are inferior to our proposed method. Finally, using the
proposed method to identify novel prostate cancer associ-
ated protein complexes; we found that 69 out of top 100
highly ranked candidate protein complexes have evidences
about the association with prostate cancer from literature.
Additional file
Additional file 1: Table S1. List of 1,704 collected human protein
complexes. Table S2. List of 282 disease phenotypes and their known
associated protein complexes. Table S3. List of 28 protein coding genes
(involved in 100 highly ranked candidate protein complexes) having
evidences about the association with prostate cancer from literature.
Table S4. List of 100 highly ranked candidate protein complexes. 69 out
of them have evidences about the association with prostate cancer from
literature. Table S5. List of protein complexes having evidences about
the association with prostate cancer from literature in 200 randomly
selected sets of 100 protein complexes.
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